Id be happy to see them move away from myc as a banner( but keep working on it), or at least reduce the emphasis on it. They titled themselves as an oncology company targetting myc when i would have preffered they title themselves as a fpp peptide specialist with a branch working on myc conjugated with fpp. I think deals or income must surely be much closer with fpp than myc. It always seemed like a mistake to advertise as oncology, especiazlly when our only milestone for the last few years came from genentech and antimicrobials. Maybe even they are wondering if we know what we are??
Id be happy to see them move away from myc as a banner( but keep...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
-0.020(1.56%) |
Mkt cap ! $729.0M | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.29 | $1.25 | $4.616M | 3.649M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19940 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.27 | 1008 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |